GlassScriptPhysician profile
Paul Presti
NPI 1710035084
$1,872.53
in general payments reported to CMS, 2019-2025
14 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Facial Plastic Surgery provider received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.35 · 2020: $116 · 2021: $102 · 2022: $258 · 2023: $507 · 2024: $439 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309 · Education: $51.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,308.53 |
| Education | $51.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $618.98 | 2019-2025 | Dupixent |
| Abbvie INC. | $438.16 | 2023-2025 | |
| Genzyme Corporation | $275.68 | 2022-2025 | |
| Optinose US, INC. | $199.54 | 2020-2025 | |
| Aerin Medical INC. | $161.38 | 2023 | |
| Amgen INC. | $48.28 | 2025 | Tezspire |
| Merz North America, INC. | $22.41 | 2019 | |
| Lilly USA, LLC | $17.86 | 2023 | Olumiant, Taltz |
| Galderma Laboratories, L.P. | $17.58 | 2021 | |
| Paratek Pharmaceuticals, INC. | $16.85 | 2025 | Xhance |
| Acclarent, INC | $15.98 | 2020 | |
| Incyte Corporation | $15.52 | 2024 | Opzelura |
| Leo Pharma INC. | $14.96 | 2024 | Adbry |
| Mayne Pharma Commercial LLC | $9.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Presti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.